Vendor Intelligence Report: Yiwu Aozuo Trading Co

Published 12 Jun 2026. 28-page investigative report on who is behind Yiwu Aozuo Trading Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 113 Finnrick lab tests, Yiwu Aozuo’s overall pass rate is 85%. The headline is respectable, but the catalog is uneven. GHK-Cu and Tirzepatide are the most defensible Aozuo choices in the current record; TB-500 and Tesamorelin are weak enough that a buyer should not generalize from the better products. The stricter-methodology view turns the issue from simple purity into dosing confidence.

The corporate story creates a separate concern. A Shenzhen registration profile, young Aozuo domain chronology, and duplicated export-site copy tell a different story from the storefront’s more-than-10-years manufacturer posture and Yiwu branding. The report resolves the legal entity, shareholder, registration anchor, apartment-address issue, and capitalization mismatch without overreading every location inconsistency as fraud.

The web and reputation files are buyer-control issues, not generic alarm. Multiple Aozuo domains share template DNA, including an unreplaced ISAIAH pneumatic-fittings artifact, and the main cluster sits beside unrelated export businesses. A scam-flagged copycat site adds authenticity risk. Community reports are mixed: test-backed Tirzepatide positives sit alongside cloudy or jelly-like reconstitution, refund friction, possible sterile-water supply, and an AOD-9604 allegation that remains open. No affiliate network or vendor-specific sanctions hit surfaced.

Inside the full report:

  • Appendix A per-product Finnrick data, methodology-divergence charts, and rating trajectories for all 9 products
  • Shenzhen corporate profile bridge, registration details, shareholder record, and Yiwu-versus-Shenzhen location analysis
  • Domain-cluster and shared-hosting analysis covering Aozuo sister sites and ISAIAH template artifacts
  • Copycat-domain review and authenticity controls for avoiding payment diversion
  • Community evidence review covering reconstitution complaints, WA/BA diluent concerns, refunds, and the AOD-9604 open lead
  • Promotion, sanctions, registry-access, import-record, and unexplained US-phone-number checks

Risk assessment

  • Product-specific quality consistency risk — high: High concern for TB-500 (45.65%), Tesamorelin (52.72%), BPC-157 (58.45%), and Cagrilintide (62.87%); stronger current Aozuo signals are GHK-Cu and Tirzepatide, not the whole catalog.
  • Corporate-identity and claims-accuracy risk — high: The linked Shenzhen entity was incorporated Apr. 21, 2025 with RMB 100,000 capital while storefronts claim more than 10 years and market Yiwu/manufacturer identity.
  • Copycat and brand-confusion risk — medium: A scam-flagged globalnwaozuo.com impersonator exists, and Aozuo does not present a clear canonical-domain or authorized-channel list across its similar domains.
  • Reconstitution and after-sales handling risk — medium: Community reports describe turbid or jelly-like reconstitutions, possible sterile-water substitution, refund resistance, and advice that would be unsafe if accurately reported.